Navigation Links
Pharmaxis Investor Conference Call
Date:4/6/2009

SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL) will release its March 2009 Quarterly Report to Shareholders on the afternoon of Wednesday 8th April 2009. Dr Alan Robertson will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday 9th April at 8.00am (Sydney), (Wednesday 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West Coast).

    Telephone access (toll free) details are below:
    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    -- Online (global access):
      http://services.choruscall.com/links/pharmaxis090409.html

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.

    CONTACT:

     Pharmaxis Investor Relations
     Tel:     +61-2-9454-7200
     Fax:     +61-2-9451 3622,
     Email:   Investor.Relations@Pharmaxis.com.au
     Website:http://www.pharmaxis.com.au

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmaxis Appoints French Distributor for Aridol(TM)
2. Pharmaxis Builds Senior Management Team
3. Pharmaxis Investor Conference Call
4. Pharmaxis Aridol Approved for Sale in Switzerland
5. Pharmaxis Investor Conference Call
6. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
7. New Pharmaxis Board Appointment
8. Pharmaxis Aridol Authorised for Sale in Germany
9. Pharmaxis First Steps into China
10. Pharmaxis to Apply to Market Bronchitol in Australia
11. Pharmaxis Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member. David ... ( North America ), will serve as ... "We,re pleased to have Ipsen and Dr. Cox ... Leonard . "We welcome their insights in helping us ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for Parkinson’s ... study published in STEM CELLS suggests that human neural stem cell (hNSC) transplantation ... produce more neural cells. , Strategies involving transplantation of these cells into ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished life ... operations. , Avomeen is a leader in a wide range of services ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a ... ) and the US National Institutes of Health. Continue ... ... ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
Breaking Biology News(10 mins):